October 17, 2011Date Released: 17 October 2011
MESSAGE FROM THE DIRECTOR
Stan Gerson, MD
Please note the School of Medicine announcement of the new Weatherhead Institute for Family Medicine and Community Health to be located at CWRU. The gift of Al and Celia Weatherhead will propel our remarkable Department of Family Medicine into an even greater international leader in research of disease prevention and early detection. The Department of Family Medicine is at the heart of our Program in Cancer Prevention and Control, and this support to the department will provide a solid foundation for further expansion of the cancer research component of the mission of this new Institute. We are fortunate that these resources will enrich the department and its investigative and outreach units.Case CCC Part of Newly Awarded Consortium Contract to Determine Clinical Benefit of New Cancer Drugs
The Case CCC, in partnership with The Ohio State University, Georgetown University, and Roswell Park, is pleased to announce the receipt of an N01 consortium contract to conduct Phase 2 and early clinical trials of NCI Cancer Therapy Evaluation Program (CTEP) agents to determine their clinical benefit.
OSU, which previously held an N01, will serve as the lead site on this contract. The Case CCC team will be led by Dr. Neal Meropol, along with UH Site PI Dr. Afshin Dowlati and Cleveland Clinic Site PI Dr. Robert Dreicer.
Only seven centers in the United States received an N01 contract. Along with the U01 previously awarded to Afshin Dowlati, this award places us in a small group of NCI-designated cancer centers with this dual recognition as a center focused on innovative therapeutics.NIH-funded Study Shows Increased Prostate Cancer Risk from Vitamin E Supplements
Last week, the NCI released an announcement on new findings related to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Researchers saw a 17 percent increase of prostate cancers in men who took the daily allotted 400 international units (IUs) of vitamin E versus men who took a placebo. These results were published in the October 12, 2011 issue of the Journal of the American Medical Association.
Dr. Eric Klein, chair of the Glickman Urological and Kidney Institute at the Cleveland Clinic and study co-chair for SELECT, recommends that men who participated in SELECT stop taking the dosage of vitamin E and continue seeing their primary care physician or urologist. [more]
CASE CCC IN THE NEWS
Researchers Discover That Same Gene Has Opposite Effects in Prostate, Breast Cancers
Vitamin E May Increase Risk of Prostate Cancer
Beating Cancer: FAQ From the On-line Chat
Video: What the Future Holds for Breast Cancer Treatment
MARK YOUR CALENDARSCancer Center Seminar Series: Flushing Oral Oncology Drugs Down the Toilet
Friday, October 21
Please join us Friday, October 21 at the next Cancer Center Seminar Series featuring Mark J. Ratain, MD. Dr. Ratain will present Flushing Oral Oncology Drugs Down the Toilet.
Dr. Ratain has been a faculty member in the Department of Medicine at The University of Chicago since 1986, and is currently the Leon O. Jacobson Professor of Medicine, the Director of the Center for Personalized Therapeutics, and Chief Hospital Pharmacologist. In addition, he serves as the Associate Director for Clinical Sciences in the University's Comprehensive Cancer Center.The Cancer Genome Atlas Program: Comprehensive Cancer Genomics Data on 5,000+ Cases Across 24 Cancer Subtypes
The NCI Office of Cancer Centers presents the next webinar in its Learning Series, The Cancer Genome Atlas Program: Comprehensive Cancer Genomics Data on 5,000+ Cases Across 24 Cancer Subtypes, on Tuesday, November 1 from 2-3:30 pm. This presentation will address The Cancer Genome Atlas (TCGA) program, which aims to complete the comprehensive genomic characterization of more than 11,000 tumors by the end of 2014.
This presentation will review the status of TCGA in general, a description of tumor types, sample criteria and biospecimen processing, and provide a summary of the discoveries from the most well developed projects. It will also provide information for how different groups can become more involved as collaborators and users of this immense, high-quality, comprehensive dataset.
The featured speakers are: Kenna Shaw, PhD, Deputy Director of The Cancer Genome Atlas Program Office, who will discuss the current projects and discoveries of the TCGA program, and Jill Barnholtz-Sloan, PhD, Associate Professor at Case Western Reserve University/University Hospitals, who will provide information about her work for the TCGA program.
Pre-registration is required.Graft vs. Host Disease Conference
The Case CCC and the Meredith A. Cowden Foundation are bringing a national educational conference on Graft vs. Host Disease (GvHD) to Cleveland on Friday, November 4, 7:30 am to 5 pm, at the Renaissance Cleveland Hotel. The conference will unite leading specialists in hematology, oncology, bone marrow transplantation and immunology from more than a dozen of the nation's top cancer research centers and educational institutions to present information on cutting-edge research and treatments. Registration (includes CME credits), is $100 for physicians and pharmacists, $75 for nurses and other healthcare professionals and $25 for students. Please make every effort to register and attend.
FUNDING OPPORTUNITIESAACR-FNAB Career Development Award for Translational Cancer Research
The AACR–FNAB Career Development Award for Translational Cancer Research is open to junior faculty who are in the first 4 years of a faculty appointment (at the start of the grant term). Research projects are restricted to translational cancer research focused on any individualized therapeutic area. Proposed project must have implications for individualized cancer treatment and must make use of human biopsies or samples, such as needle biopsies or circulating cancer cells. In vivo primary tumor explants meet these criteria, but xenografts from established cell lines do not.
Deadline: November 1Doris Duke Clinical Scientist Development Award
The Doris Duke Clinical Scientist Development Awardprovides grants to junior physician-scientists to facilitate their transition to independent clinical research careers. CWRU may nominate TWO candidates for this award.
Internal Deadline: November 2AACR–Conquer Cancer Foundation of ASCO Young Investigator Translational Cancer Research Award
The AACR–Conquer Cancer Foundation of ASCO Young Investigator Translational Cancer Research Award provides funding to promising investigators to encourage and promote quality research in clinical oncology. The purpose of this award is to fund physician–scientists during the transition from a fellowship program to a faculty appointment. The Award is open to physicians or physicians holding a combined MD/PhD. Applicants must be working in an oncology laboratory or clinical research setting in an academic medical institution. Research projects are restricted to translational cancer research.
Deadline: November 15Connie Henke Yarbro Excellence in Cancer Nursing Mentorship Award
The Oncology Nursing Society (ONS) Foundation is accepting nominations for the Connie Henke Yarbro Excellence in Cancer Nursing Mentorship Award. The purpose of this award is to recognize and support excellence in the mentorship of oncology nurses.
Nominees may be any oncology nurse (ONS member or non-member) or ONS Chapter or SIG that meet the following qualifications:
Deadline: January 15, 2012Case CCC Clinical Trials Protocol Specific Research Support Funding
The Case CCC is encouraging investigators to submit Letters of Intent for the Protocol Specific Research Support (PSRS) funding for Year 2011. The budgeted funds are for the conduct of early phase clinical trials and restricted to support research nurses and data managers directly involved in the conduct of these clinical trials. Studies developed jointly between UH and CCF with planned accrual at both institutions will be prioritized. Please direct questions and requests for information about the funding process to Katarzyna Karelus, Administrative Director, Case CCC Clinical Research Office, at (216) 844-4176 or email@example.com.
ANNOUNCEMENTSLazarus Appointed Director of Novel Cell Therapies
Dr. Hillard Lazarus was recently appointed the first Director of Novel Cell Therapies for UHCMC and Seidman Cancer Center. In this position, Dr. Lazarus will work with the Cell Therapy Integrated Service, a cell production facility where he will continue to serve as medical director, and with hospital and cancer leadership developing new cell therapies, in the disciplines of cancer, hematology, neurology, genitourinary diseases, orthopedics, and cardiology.Miller Named CWRU VP of Research
Dr. Robert Miller was recently named as CWRU Vice President of Research. Dr. Miller has served as vice dean for research at the School of Medicine since 2007.Clinical Research Education Needs Assessment Survey
CWRU, Cleveland Clinic, UH and MetroHealth Medical Center have partnered to form the Clinical and Translational Science Collaborative (CTSC). One of the goals of the CTSC is to strengthen the training and career pathways for all clinical and translational research team members, including research assistants, study coordinators, data managers, and study recruiters. The CTSC asks that you participate in a survey to assess interest in a certificate program in clinical research fundamentals. A certificate would demonstrate standard competency among the partner institutions. All responses will be anonymous; candid comments are welcome. The survey will be active through November 18.Laser Capture Microdissection Service Replacement System Demonstrations
The Laser Capture Microdissection (LCM) Service is in the process of vetting LCM systems with a view towards purchasing a replacement for the Arcturus Veritas system. Two comparable replacement systems are being considered: Molecular Medical Instruments (MMI) and Leica LMD6500. Each vendor will be offering onsite demonstrations in the coming weeks. The MMI demonstration will be November 2-3, and Leica is tentatively set for the week of November 7. Investigators are encouraged to bring their own prepared slides for processing during the demonstration period. Please contact Patrick Leahy, Director of the LCM Service, at (216)368-0761 or firstname.lastname@example.org with any questions or for more information.
**All events are open to anyone interested in attending
Pathology Research Seminar
Physiology and Biophysics Seminar
Immunology Seminar Series
Cytokine Signaling, Inflammation, and Cancer Focus Group Meeting
Hematology and Oncology Division Research Conference canceled
Immunology Visiting Professor Seminar Series
Nuclear Receptor Signaling and Hormone Responsive Cancers Focus Group Meeting
TGFβ Focus Group Meeting
Molecular and Microbiology Seminar
Hematology/Oncology Fellows Conference
Taussig Cancer Institute Grand Rounds
Cancer Center Seminar Series
Cancer Center Research in Progress Seminar
Case CCC Calendar
UPCOMING CANCER CENTER SYMPOSIUMS & EVENTS
Graft Versus Host Disease Conference
ADDITIONAL UPCOMING SEMINARS & EVENTS
8th International Conference of the Society for Integrative Oncology: Innovating Integrative Oncology: New Science, New Solutions
PREVIOUSLY ANNOUNCED OPPORTUNITIES
DOD LCRP Concept Award
NCI Provocative Questions Project
NIH BULLETIN – Notices and Funding Opportunities
Request for Information (RFI): To Solicit Input on Partnerships between Extramural and NIH Intramural Investigators Utilizing the NIH Clinical Center (NOT-OD-12-005) National Institutes of Health
Administrative Supplements to NCI-funded Research Projects: Funding to Advance Research on Cancers in Women (NOT-CA-12-001)
Notice of Availability of Administrative Supplements for U.S. - Russia Collaborative HIV/AIDS Research (NOT-MH-12-001)
HELP US HELP YOU!
If you have a new grant, recently won an award, or have other newsworthy items, please let us know so we can publicize them in the newsletter and other media outlets. You deserve the accolades!
Send items to email@example.com.